Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

News Physiol Sci 16: 191-194, 2001;
1548-9213/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halin, C.
Right arrow Articles by Neri, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halin, C.
Right arrow Articles by Neri, D.
News in Physiological Sciences, Vol. 16, No. 4, 191-194, August 2001
© 2001 Int. Union Physiol. Sci./Am. Physiol. Soc.

Antibody-Based Targeting of Angiogenesis

Cornelia Halin1, Luciano Zardi2 and Dario Neri1

1 Institute of Pharmaceutical Sciences, Department of Applied Biosciences, Swiss Federal Institute of Technology, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland; and
2 Laboratorio di Biologia Cellulare, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi 10, 16132 Genova, Italy
The selective targeting of neovasculature opens new avenues for the diagnosis and therapy of angiogenesis-related diseases such as cancer, blinding ocular disorders, and rheumatoid arthritis. Here we review recent advances in the identification of markers of angiogenesis as well as in the isolation and use of antibodies (and their derivatives) for the in vivo targeting of both tumoral and nontumoral neovasculature.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Wagner, P. Schulz, A. Scholz, B. Wiedenmann, and A. Menrad
The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
Clin. Cancer Res., August 1, 2008; 14(15): 4951 - 4960.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R. E. Kontermann
Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells
Protein Eng. Des. Sel., May 1, 2004; 17(5): 433 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Schmitt-Sody, S. Strieth, S. Krasnici, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, and M. Dellian
Neovascular Targeting Therapy: Paclitaxel Encapsulated in Cationic Liposomes Improves Antitumoral Efficacy
Clin. Cancer Res., June 1, 2003; 9(6): 2335 - 2341.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Micheletti, M. Poli, P. Borsotti, M. Martinelli, B. Imberti, G. Taraboletti, and R. Giavazzi
Vascular-targeting Activity of ZD6126, a Novel Tubulin-binding Agent
Cancer Res., April 1, 2003; 63(7): 1534 - 1537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Santimaria, G. Moscatelli, G. L. Viale, L. Giovannoni, G. Neri, F. Viti, A. Leprini, L. Borsi, P. Castellani, L. Zardi, et al.
Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer
Clin. Cancer Res., February 1, 2003; 9(2): 571 - 579.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online